Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Baypress; Belgium: Baypress; Bulgaria: Nitrendipin, Ravena; Czech Republic: Baypress, Lusopress, Nitrendipin, Nitrepress, Nitresan, Unipres; Denmark: Baypress; Estonia: Lusopress, Nitresan; France: Baypress, Nidrel, Nitrendipine; Germany: Bayotensin, Baypress, Jutapress, Nitre-PUREN, Nitregamma, Nitren Lich, Nitrendidoc, Nitrendipin, Nitrensal, Nitresan, Nitripress; Greece: Baypress, Lostradyl, Nelconil, Potional; Hungary: Baypress, Nevin, Unipress; Italy: Baypress; Latvia: Lusopress, Nitresan; Lithuania: Lusopress, Nitresan; Luxembourg: Baypress; Netherlands: Baypress; Poland: Baypress, Nitrendypina, Nitresan, Unipres; Portugal: Farnitran, Hyperdipina; Slovakia: Lusopress, Nitresan, Unipres; Slovenia: Unipres; Spain: Baypresol, Gericin, Niprina, Nitrendipino, Tensogradal, Vastensium.

Latin America

Argentina: Nirapel, Nitrendil; Brazil: Caltren, Nitrencord, Nitrendipino.


Japan: Balodipine, Balotein, Baylotensin, Bayniroad, Cobatensin, Dosperopin, Dowtensine, Ecatelisin, Ellenal, Hishiromin, Nilzipin, Nitopress, Nitotelocin, Nitrenal, Shetlazorna.

Drug combinations

Nitrendipine and Enalapril


Nitrendipine: C~18~H~20~N~2~O~6~. Mw: 360.36. (1) 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (±)-; (2)(±)-Ethyl methyl 1,4dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. CAS-39562-70-4 (1981).

Pharmacologic Category

Calcium Channel-Blocking Agents; Dihydropyridines. (ATC-Code: C08CA08).

Mechanism of action

Dihydropyridine calcium channel-blocking agent with actions similar to nifedipine.

Therapeutic use


Pregnancy and lactiation implications

Enters breast milk (not recommended).

Unlabeled use


Hypersensitivity to any component of the formulation or other calcium channel-blocking agents. Hypotension. Advanced aortic stenosis.

Warnings and precautions

Reduce dosage in the elderly. Caution in liver insufficiency, digital ischemia, nonobstructive hypertrophic cardiomyopathy, Duchenne muscular dystrophy, or in combination with β-blocking agents. Blood pressure lowering must be done at a rate appropriate for the patient’s clinical condition. May cause dizziness or fatigue.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart